首页> 外文期刊>Cancer Cell International >Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
【24h】

Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis

机译:PD-L1对潜在肝癌切除术后肝癌患者的预后作用:一项荟萃分析

获取原文
           

摘要

A series of studies has investigated the prognostic role and clinical significance of programmed death ligand 1 (PD-L1) in hepatocellular carcinoma (HCC). However, the results were inconsistent. We aimed to clarify the prognostic role of PD-L1 and relationship between PD-L1 expression and several important clinicopathological features. PubMed, EMBASE and the Science Citation Index Expanded were systematically searched. All cohort or case–control studies comparing the prognosis and clinical features between the high PD-L1 and low PD-L1 groups were included. Publication bias was evaluated using funnel plots and Begg’s test. Subgroup analysis, sensitivity analysis and meta-regression analysis were performed. Seventeen studies including 2979 patients were eligible. The overall survival (OS) was not significantly different between the high and low PD-L1 groups (hazard ratio [HR]: 1.27; 95% confidence interval [CI] 0.98–1.65: P?=?0.07) with significant heterogeneity (P??0.001; I2?=?81%). The recurrence-free survival (RFS) was not significantly different between the high and low PD-L1 groups (HR: 1.22; 95% CI 0.97–1.53; P?=?0.09) with significant heterogeneity (P??0.001; I2?=?78%). The expression of PD-L1 was found to be significantly correlated with alpha-fetoprotein, hepatitis history, and tumour-infiltrating lymphocytes. Begg’s test found no significant publication bias for OS and RFS. Sensitivity analysis established the robustness of our results. Subgroup analysis and meta-regression analysis found the region of research as a significant contributor to inter-study heterogeneity in RFS, indicating some racial differences in the prognostic role of PD-L1. Our study found no significant prognostic role of PD-L1 in HCC patients after potential curative hepatectomy based on our included studies. The expression of PD-L1 was significantly correlated with AFP, hepatitis history, and TILs. The prognostic role of PD-L1 in HCC warrants further investigation.
机译:一系列研究调查了程序性死亡配体1(PD-L1)在肝细胞癌(HCC)中的预后作用和临床意义。但是,结果不一致。我们旨在阐明PD-L1的预后作用以及PD-L1表达与一些重要的临床病理特征之间的关系。系统搜索了PubMed,EMBASE和《科学引文索引》。所有队列研究或病例对照研究都比较了高PD-L1组和低PD-L1组之间的预后和临床特征。使用漏斗图和Begg检验评估发布偏倚。进行亚组分析,敏感性分析和Meta回归分析。包括2979名患者在内的17项研究符合条件。高和低PD-L1组之间的总生存率(OS)没有显着差异(危险比[HR]:1.27; 95%置信区间[CI] 0.98–1.65:P <= 0.07),且异质性显着(P ≤0.001,I 2≤81%。高PD-L1组和低PD-L1组之间的无复发生存率(RFS)无显着差异(HR:1.22; 95%CI 0.97-1.53​​; P <= 0.09),且异质性显着(P <0.001); I2 ?=?78%)。发现PD-L1的表达与甲胎蛋白,肝炎病史和肿瘤浸润淋巴细胞显着相关。 Begg的测试发现OS和RFS没有明显的发布偏见。敏感性分析确定了我们结果的稳健性。亚组分析和荟萃回归分析发现,该研究领域是导致RFS研究间异质性的重要因素,表明PD-L1的预后作用存在种族差异。根据我们纳入的研究,我们发现潜在的根治性肝切除术后PD-L1在HCC患者中没有明显的预后作用。 PD-L1的表达与AFP,肝炎病史和TILs显着相关。 PD-L1在肝癌中的预后作用值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号